The DOD Congressionally Directed Medical Research Programs (CDMRP), is seeking individuals who are survivors of and received treatment for Hepatitis “B” or Hepatitis “C” to participate as consumer reviewers of applications submitted to fund research dealing with the treatment and rehabilitation of these diseases/ conditions. Consumer reviewers assess and comment on proposed treatment possibilities that can most improve the quality of life for living with these conditions. In accordance with federal government guidelines, a consultant fee will be provided and approved travel expenses of panel members will be reimbursed. Additional information is on the CDMRP Website: http://cdmrp.army.mil/
As a unified, coordinated global event, World Hepatitis Day on the 28th July has only been observed since 2010. Concerned at the disparity between increasing mortality from viral hepatitis and the glacial pace of international efforts to combat these diseases, the World Health Assembly (the legislative body of the WHO) adopted the first resolution on viral hepatitis, establishing World Hepatitis Day to “provide an opportunity for education and greater understanding of viral hepatitis as a global public health problem, and to stimulate the strengthening of preventive and control measures of this disease in Member States.” The intervening 7 years have seen World Hepatitis Day and associated campaigns increasingly capturing public imagination; as the content published here makes abundantly clear, however, there is a long way to go before viral hepatitis commands the same attention as other communicable diseases with similar global mortality and morbidity burdens, such as malaria, HIV or tuberculosis.
Many members of the public would find the statistics on the burden of viral hepatitis appalling. An estimated 3.5% of the global population are infected with the hepatitis B virus (HBV), corresponding to ~257 million people. In Africa and the Western Pacific, prevalence rises to ~6% of the general population. The WHO estimates that up to 65 million women of childbearing age might also be chronically infected, risking transmission of HBV to their babies in the absence of preventative measures. In 2015 alone, HBV killed ~884,000 people.
For hepatitis C, the picture is equally bleak. An estimated 71 million people worldwide are infected with HCV, with ~400,000 dying from the disease each year. As with HBV infection, prevalence differs dramatically by region, with 2.3% of people living in the WHO Eastern Mediterranean Region (which covers the Middle East, North Africa and countries in Central Asia) infected, equating to ~15 million individuals. Comparatively, prevalence in South East Asia is only 0.5%.
Hepatitis C has a catastrophic impact on people’s lives. According to UNODC’s World Drug Report, of the 12 million people injecting drugs globally, 6.1 million are living with the terrible effects of hepatitis C.
There is positive news. Advances in medicine mean there are effective treatments for this disease; including from World Health Organization (WHO), which has just recently pre-qualified the first generic hepatitis C medicine. This will hopefully ensure that many more people receive the benefits of medicine and science.
We need to remove barriers to expand hepatitis B and C prevention, testing and treatment to everyone. People in prisons should be able to access hepatitis prevention and treatment services that are equal to those offered in communities. Such efforts will help reduce the spread of hepatitis C in prison populations, but also in the wider community.
BREAKING: A total of 275 cases have been reported. Officials say most who have become ill are either homeless or illicit drug users.
SAN DIEGO COUNTY, CA – Eight people have now died from a hepatitis A outbreak in San Diego County, health officials announced Friday.
According to the County Health and Human Services Agency, 275 cases have been reported, with 194 people hospitalized during the outbreak. All eight people who have died had underlying medical conditions at the time of their death.
Collaboration to combine Janssen’s vaccine technologies with MVA-BN® technology from Bavarian Nordic to advance potential new vaccine regimens
RARITAN, NJ – July 26, 2017 – Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has entered into a worldwide exclusive license and collaboration agreement with Bavarian Nordic to leverage their MVA-BN® technology with Janssen’s own AdVac® and DNA-based vaccine technologies in the development and commercialization of potential new vaccine regimens against hepatitis B virus (HBV) and the human immunodeficiency virus (HIV-1). This agreement stems from successful and ongoing collaborations between the companies to develop vaccines to address Ebola and Human Papillomavirus (HPV).
(Reuters) – Available data supports the safety of Dynavax Technologies Corp’s experimental hepatitis B vaccine when administered to adults, a panel of expert advisers to the U.S. Food and Drug Administration said on Friday.
Much of the panel discussion focused on the need for Dynavax to carefully track patient outcomes due to concerns about safety of the vaccine, which has been rejected twice before by the regulatory agency.
The advisory committee voted 12 to 1, including one emailed vote and three abstentions, that data supports the safety of the vaccine, Heplisav-B, for adults 18 years and older. A prior panel voted 13 to 1 that clinical trial data supports the vaccine’s effectiveness, Dynavax said.